食管腺癌新辅助放化疗后结局预测:肿瘤反应与生存之间的相互作用
本研究评估277例接受新辅助CROSS方案后行食管切除术的食管腺癌患者,按改良Ryan评分分组肿瘤退缩评分(TRS),并按PERCIST标准评估代谢反应。病理完全缓解(TRS 0)患者总生存期长于TRS 1、2、3组;内镜活检印戒细胞特征和区域淋巴结SUV摄取较高与病理残留肿瘤相关,淋巴结站SUVmax较高与总生存期下降独立相关。
要点
- 277例中TRS 0(完全缓解)66例(23.8%),TRS 1为78例(28.1%),TRS 2为97例(35%),TRS 3为36例(13%)。
- TRS 0患者总生存期长于TRS 1(P=.010)、TRS 2(P<.001)和TRS 3(P=.005)。
- 内镜活检印戒细胞特征(OR 7.54;P=.012)和区域淋巴结SUV摄取较高(OR 1.42;P=.007)与病理残留肿瘤显著相关。
核心结论
- 病理完全缓解患者总生存期延长,而其他TRS类别间未检测到生存差异。
- 初始分期时印戒细胞存在和区域淋巴结SUV摄取较高可预测病理残留病变和较短总生存期,提示这些患者需要新的治疗策略。
研究设计与样本
- 回顾性评估2016年至2020年间接受新辅助CROSS方案后因食管腺癌行食管切除术的患者。
- 肿瘤退缩评分按改良Ryan评分分组,代谢反应按PERCIST标准评估。
- 收集内镜超声、内镜活检和正电子发射断层扫描(原发灶和区域淋巴结标准化摄取值[SUV])变量。
- 研究人群共277例患者。
主要发现
- TRS 0(完全缓解)66例(23.8%),TRS 1(部分缓解)78例(28.1%),TRS 2(反应差)97例(35%),TRS 3(无反应)36例(13%)。
- 总生存分析中,TRS 0患者生存期长于TRS 1(P=.010)、TRS 2(P<.001)和TRS 3(P=.005)。
- 多变量逻辑回归中,内镜活检印戒细胞特征(OR 7.54;P=.012)和区域淋巴结SUV摄取较高(OR 1.42;P=.007)与病理残留肿瘤(TRS 1、2或3)显著相关。
- 多变量Cox回归中,代谢最活跃淋巴结站SUVmax较高(HR 1.08;P=.005)与总生存期下降独立相关,而病理完全缓解(HR 0.61;P=.021)与较高总生存期独立相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The prognostic value of tumor regression scores (TRS) in patients with esophageal adenocarcinoma (EAC) who underwent neoadjuvant chemoradiation remains unclear. We sought to investigate the prognostic value of pathologic and metabolic treatment response among EAC patients undergoing neoadjuvant chemoradiation. METHODS: Patients who underwent esophagectomy for EAC after neoadjuvant CROSS protocol between 2016 and 2020 were evaluated. TRS was grouped according to the modified Ryan score; metabolic response, according to the PERCIST criteria. Variables from endoscopic ultrasound, endoscopic biopsies, and positron emission tomography (primary and regional lymph node standardized uptake values [SUVs]) were collected. RESULTS: The study population comprised 277 patients. A TRS of 0 (complete response) was identified in 66 patients (23.8%). Seventy-eight patients (28.1%) had TRS 1 (partial response), 97 (35%) had TRS 2 (poor response), and 36 (13%) had TRS 3 (no response). On survival analysis for overall survival (OS), patients with TRS 0 had longer survival compared to those with TRS 1, 2, or 3 (P = .010, P < .001, and P = .005, respectively). On multivariable logistic regression, the presence of signet ring cell features on endoscopic biopsy (odds ratio [OR], 7.54; P = .012) and greater SUV uptake at regional lymph nodes (OR, 1.42; P = .007) were significantly associated with residual tumor at pathology (TRS 1, 2, or 3). On multivariate Cox regression for predictors of OS, higher SUVmax at the most metabolically active nodal station (hazard ratio [HR], 1.08; P = .005) was independently associated with decreased OS, whereas pathologic complete response (HR, 0.61; P = .021) was independently associated with higher OS. CONCLUSIONS: Patients with pathologic complete response had prolonged OS, whereas no difference in survival was detected among other TRS categories. At initial staging, the presence of signet ring cells and greater SUV uptake at regional lymph nodes predicted residual disease at pathology and shorter OS, suggesting the need for new treatment strategies for these patients.
引用
- Solomon D, Deeb AL, Tarabine K, et al. Predicting outcomes in esophageal adenocarcinoma following neoadjuvant chemoradiation: Interactions between tumor response and survival. J Thorac Cardiovasc Surg. 2023. PMID: 37967764. doi:10.1016/j.jtcvs.2023.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。